Recent Biotech Financings: Clavis, Halozyme, Hyperion And GenScript
This article was originally published in The Pink Sheet Daily
Taking advantage of the buzz associated with positive clinical trial data or enthusiasm for a business model, these four biotechs added to their coffers in recent weeks.
You may also be interested in...
WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.